[go: up one dir, main page]

WO2008118785A3 - Methods for treating depression using immediate-impact treatments and d-cycloserine - Google Patents

Methods for treating depression using immediate-impact treatments and d-cycloserine Download PDF

Info

Publication number
WO2008118785A3
WO2008118785A3 PCT/US2008/057844 US2008057844W WO2008118785A3 WO 2008118785 A3 WO2008118785 A3 WO 2008118785A3 US 2008057844 W US2008057844 W US 2008057844W WO 2008118785 A3 WO2008118785 A3 WO 2008118785A3
Authority
WO
WIPO (PCT)
Prior art keywords
immediate
methods
cycloserine
impact
treating depression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/057844
Other languages
French (fr)
Other versions
WO2008118785A2 (en
Inventor
Jason P Mcdevitt
Michael Davis
Kerry J Ressler
Nathan Andrew Shapira
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TIKVAH THERAPEUTICS
Original Assignee
TIKVAH THERAPEUTICS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TIKVAH THERAPEUTICS filed Critical TIKVAH THERAPEUTICS
Publication of WO2008118785A2 publication Critical patent/WO2008118785A2/en
Publication of WO2008118785A3 publication Critical patent/WO2008118785A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Methods are provided for treating depression in humans. The methods comprise administering D-cycloserine to a subject and administering an immediate-impact depression treatment. Exemplary immediate-impact treatments for depression include administration of ketamine, as well as non-pharmacologic treatments such as electroconvulsive shock therapy.
PCT/US2008/057844 2007-03-23 2008-03-21 Methods for treating depression using immediate-impact treatments and d-cycloserine Ceased WO2008118785A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89655607P 2007-03-23 2007-03-23
US60/896,556 2007-03-23

Publications (2)

Publication Number Publication Date
WO2008118785A2 WO2008118785A2 (en) 2008-10-02
WO2008118785A3 true WO2008118785A3 (en) 2008-12-24

Family

ID=39789245

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/057844 Ceased WO2008118785A2 (en) 2007-03-23 2008-03-21 Methods for treating depression using immediate-impact treatments and d-cycloserine

Country Status (1)

Country Link
WO (1) WO2008118785A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11974551B2 (en) 2011-11-21 2024-05-07 The Institute For Ethnomedicine L-serine compositions, methods and uses for treating neurodegenerative diseases and disorders

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2011104298A1 (en) * 2010-02-24 2011-09-01 Universität Zürich Prevention and treatment of diseases caused by elevated levels of deoxy-sphingolipids
KR102424765B1 (en) * 2013-04-12 2022-07-22 이칸 스쿨 오브 메디슨 엣 마운트 시나이 Method for treating post-traumatic stress disorder
WO2015031410A1 (en) 2013-08-26 2015-03-05 Amorsa Therapeutics, Inc. Single-layer oral dose of neuro-attenuating ketamine
US11110070B2 (en) 2015-11-17 2021-09-07 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms
CN105476976B (en) * 2015-12-22 2018-09-25 广州瑞尔医药科技有限公司 Pharmaceutical composition and its preparation method and application
US11622948B2 (en) 2017-11-09 2023-04-11 The Trustees Of Columbia University In The City Of New York Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders
US11491120B2 (en) 2017-11-09 2022-11-08 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders in females
CA3154457C (en) * 2019-11-27 2024-06-25 Neurorive Inc Combination therapy of cycloserine and lithium for the treatment of depression

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999052519A2 (en) * 1998-04-14 1999-10-21 The General Hospital Corporation Methods for treating neuropsychiatric disorders
US20050222270A1 (en) * 2004-02-26 2005-10-06 Olney John W Prolonged administration of NMDA antagonist drug and safener drug to create improved stable neural homeostasis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999052519A2 (en) * 1998-04-14 1999-10-21 The General Hospital Corporation Methods for treating neuropsychiatric disorders
US20050222270A1 (en) * 2004-02-26 2005-10-06 Olney John W Prolonged administration of NMDA antagonist drug and safener drug to create improved stable neural homeostasis

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ARCHIVES OF GENERAL PSYCHIATRY, vol. 63, no. 8, August 2006 (2006-08-01), pages 856 - 864, ISSN: 0003-990X *
BIOLOGICAL PSYCHIATRY, vol. 47, no. 4, 15 February 2000 (2000-02-15), pages 351 - 354, ISSN: 0006-3223 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 15 February 2000 (2000-02-15), BERMAN ROBERT M ET AL: "Antidepressant effects of ketamine in depressed patients", XP002501675, Database accession no. PREV200000162237 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; August 2006 (2006-08-01), ZARATE CARLOS A JR ET AL: "A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression", XP002501674, Database accession no. PREV200600586874 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11974551B2 (en) 2011-11-21 2024-05-07 The Institute For Ethnomedicine L-serine compositions, methods and uses for treating neurodegenerative diseases and disorders

Also Published As

Publication number Publication date
WO2008118785A2 (en) 2008-10-02

Similar Documents

Publication Publication Date Title
WO2008118785A3 (en) Methods for treating depression using immediate-impact treatments and d-cycloserine
WO2008122049A3 (en) Methods and compositions for reduction of side effects of therapeutic treatments
WO2007146411A3 (en) Nanoshell therapy
WO2008054585A3 (en) Use of pegylated il-10 to treat cancer
WO2008021389A8 (en) Using pi3k and mek modulators in treatments of cancer
WO2012002760A3 (en) Method for treating and diagnosing cancer by using cell-derived microvesicles
WO2012062925A3 (en) Compounds and methods for treating pain
WO2009023509A3 (en) Therapeutic combinations useful in treating cftr related diseases
WO2006093891A3 (en) Photosensitizers for targeted photodynamic therapy
KZ24152B (en) Method of photosensitizer activation, treatment method with application of activated photosensitizer and photosensitizer application to prepare medicine
WO2009155439A3 (en) Use of nitrated lipids for treatment of side effects of toxic medical therapies
WO2007081879A3 (en) Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
GB2442915B (en) Perylenequinone derivatives and uses thereof
WO2010014595A3 (en) Methods and compositions for delivering therapeutic agents in the treatment of b-cell related disorders
WO2010032011A8 (en) Anti-fungal therapy
WO2008054711A3 (en) Combined telomerase inhibitor and gemcitabine for the treatment of cancer
WO2005089504A3 (en) Methods for the treatment of synucleinopathies
WO2010037864A3 (en) Inhibition of plgf to treat philadelphia chromosome positive leukemia
WO2008045378A3 (en) Treatment of infant hyperbilirubinemia using low dosages of stannsoporfin
WO2005089515A3 (en) Methods for the treatment of synucleinopathies
WO2007134203A3 (en) Anticancer treatments with a combination of docetaxel and ecteinascidin
WO2007130501A3 (en) Combination therapy for treatment of cancer
WO2010019717A3 (en) Combination therapy of hiv fusion/entry inhibitors targeting gp41
WO2008039994A3 (en) Targeted photodynamic therapy agent
WO2012024403A3 (en) Methods of treating cellulite

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08732664

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 08732664

Country of ref document: EP

Kind code of ref document: A2